<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00453791</url>
  </required_header>
  <id_info>
    <org_study_id>SF2105450</org_study_id>
    <nct_id>NCT00453791</nct_id>
  </id_info>
  <brief_title>The Safety and Tolerability of GW805858 in Healthy Volunteers and Mild Asthmatics</brief_title>
  <official_title>A Randomised, Single and Repeat Dose, Double-blind, Placebo Controlled Study to Assess the Safety and Tolerability of GW805858 in Healthy Volunteers and Mild Asthmatics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be the First Time in Human Study (FTIH) aiming to assess the safety and
      tolerability of GW805858 for both single and repeat dose. The study also aims to assess
      safety and tolerability in mild asthmatic subjects as well as healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">February 7, 2006</start_date>
  <completion_date type="Actual">April 10, 2006</completion_date>
  <primary_completion_date type="Actual">April 10, 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability parameters will be compared between active and placebo treatment groups using summary statistics. No formal statistical analyses of the safety and tolerability data will be performed.</measure>
    <time_frame>Up to 18 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Derived GW805858 and GW288967 PK parameters will be compared between active and placebo treatment groups using summary statistics.</measure>
    <time_frame>Pre-dose, 5,20,30,45,60,90 minutes, 2,3,4,6,8,10,12,12.5,13,14, 24 hours Post-dose on Days 1 and 28.</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Subjects receiving treatment sequence 1: Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive placebo followed by GW805858 with a starting dose of 150 micrograms administered using Metered Dose Inhaler (MDI).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving treatment sequence 2: Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive GW805858 with a starting dose of 150 micrograms followed by placebo administered using MDI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving treatment sequence 1: Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive placebo followed by GW805858 with a starting dose of 150 micrograms administered using MDI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving treatment sequence 2: Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive GW805858 with a starting dose of 150 micrograms followed by placebo administered using MDI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving GW805858: Part 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive GW805858 1200 micrograms twice daily administered using MDI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving placebo: Part 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive placebo administered using MDI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GW805858</intervention_name>
    <description>GW805858 MDI will be given with dose of 150 micrograms per metered actuation and 120 actuations per inhaler. GW805858 MDI comprises a solution of GW805858 in a liquefied hydrofluoroalkane propellant (1,1,1,2-tetrafluoroethane) which is contained in an aluminium alloy can, internally coated with a specified fluoropolymer, fitted with a metering valve.</description>
    <arm_group_label>Subjects receiving treatment sequence 2: Part 1</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 2: Part 2</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 1: Part 2</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 1: Part 1</arm_group_label>
    <arm_group_label>Subjects receiving GW805858: Part 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo MDI will be given to the subjects.</description>
    <arm_group_label>Subjects receiving treatment sequence 2: Part 1</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 2: Part 2</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 1: Part 2</arm_group_label>
    <arm_group_label>Subjects receiving placebo: Part 3</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 1: Part 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women of non-child bearing potential, aged between 18 and 60 years of age
             inclusive.

          -  Body weight = 50 kg (110 lbs) for men and = 45 kg for women and Body Mass Index (BMI)
             within the range 19.0-30.0 kg/m2 inclusive.

          -  The subject is a current non-smoker who has not used any tobacco products in the last
             year.

          -  A signed and dated written informed consent is obtained for the subject.

          -  The subject is able to understand and comply with protocol requirements and
             timetables, instructions and protocol-stated restrictions.

          -  If asthmatic, the subject must be a clinically stable asthmatic.

        Exclusion Criteria:

          -  The subject has a history of allergy to ingredients within the inhaler.

          -  The subject has received an investigational drug or participated in any other research
             trial within 30 days, prior to the first dose of current study medication.

          -  The subject has used prescription or non-prescription drugs, including vitamins,
             herbal and dietary supplements (including St John's Wort) within 14 days prior to the
             first dose of study medication.

          -  The subject has an average weekly alcohol intake of greater than 21 units if male or
             14 units if female.

          -  The subject has any history of breathing problems (e.g. history of asthmatic
             symptoms).

          -  The subject is infected with the hepatitis B, hepatitis C, or HIV virus.

          -  The subject has had a respiratory tract infection or worsening of asthma within 4
             weeks of the start of the study.

          -  The subject has a past or present disease, which as judged by the Investigator, may
             affect the outcome of this study.

          -  The subject has a history of life-threatening asthma, defined as an asthma episode
             that required intubation and/or was associated with hypercapnea, respiratory arrest or
             hypoxia seizures.

          -  The subject has taken inhaled, nasal or dermal steroids within 4 weeks or oral
             steroids within 8 weeks of the start of the study.

          -  The subject is unable to abstain from other drugs that may interfere with the conduct
             of the study.

          -  The subject has ongoing rhinitis that requires treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SW20 0NE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://gsk-clinicalstudyregister.com/study/SF2105450?search=study&amp;study_ids=SF2105450#rs</url>
    <description>Results for study SF2105450 can be found on the GSK Clinical Study Register.</description>
  </link>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2007</study_first_submitted>
  <study_first_submitted_qc>March 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2007</study_first_posted>
  <last_update_submitted>September 27, 2017</last_update_submitted>
  <last_update_submitted_qc>September 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GW805858</keyword>
  <keyword>MDI</keyword>
  <keyword>asthma</keyword>
  <keyword>surfactant</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

